ProofPilot Acquires Lokavant to Transform Clinical Trial Performance with Predictive Analytics

NEW YORK, Sept. 15, 2025 /PRNewswire/ -- ProofPilot, the leading end-to-end clinical experience platform, today announced the acquisition of Lokavant, the clinical trial intelligence company and the premier provider of predictive analytics for clinical research. This acquisition combines ProofPilot's powerful trial execution capabilities with Lokavant's advanced analytics, creating an unparalleled platform for sponsors and research organizations to optimize clinical research and accelerate the delivery of new therapies.

Spun out of Roivant in 2020, Lokavant's technology leverages historical and real-time data to deliver predictive insights, optimize study feasibility, and mitigate operational risk in study conduct. With the integration of Lokavant's advanced analytics into the ProofPilot platform, sponsors and CROs will be able to holistically build and execute complex clinical trial experiences with excellence and anticipate challenges before they occur to drive faster, more reliable outcomes.

"ProofPilot has long demonstrated a commitment to empowering sponsors and research teams with the tools they need to execute successful trials," said Chris Venezia, CEO of ProofPilot. "By bringing Lokavant's predictive analytics engine into our platform, we're equipping our customers with an industry first ability to measure and predict success in real time by combining study stakeholder behaviors and real time study data."

The combined platform delivers a data-driven approach to trial management with an intuitive experience for clinical researchers. AI-powered study forecasting supports proactive scenario planning, while users can create and manage recruitment campaigns, with real-time performance dashboards providing continuous monitoring during study execution. Additionally, the integrated platform includes study oversight capabilities, enhancing study data quality and compliance through site training driven by emerging site protocol adherence and data quality signals. This combination improves operational predictability, reduces risk, and ensures trials generate reliable results—ultimately accelerating delivery of innovative therapies to patients.

"We are excited to see Lokavant join forces with ProofPilot," said Alex Gasner, EVP Roivant Health. "This move aligns deeply with Roivant's mission—to improve the lives of patients by accelerating the development and commercialization of medicines that matter. By combining Lokavant's powerful, data-driven insights with ProofPilot's trial experience platform, biopharma will be better positioned to deliver innovative medicines and technologies faster, more precisely, and with greater impact for patients everywhere."

"This is a transformative moment for both ProofPilot and Lokavant," said Rohit Nambisan, CEO & Co-Founder of Lokavant. "By combining ProofPilot's innovative trial platform with Lokavant's predictive analytics, we are giving sponsors and CROs unprecedented clarity and foresight into study performance. Together, we empower them to plan smarter, adapt faster, and bring new therapies to patients more efficiently—setting a new standard for how clinical trials are designed and executed."  

With the acquisition of Lokavant, ProofPilot strengthens its position as a market leader in clinical trial innovation, offering a fully integrated, end-to-end platform that combines digital trial planning, execution, and predictive intelligence to maximize operational performance.

About ProofPilot

ProofPilot modernizes the way clinical trials are launched and managed via its Clinical Experience Platform. With a focus on simplifying site operations and reducing patient burden, the platform deploys a seamless, branded experience from recruitment through close out, leading to faster enrollment timelines, higher compliance rates, and increased quality for your trials. Learn more at www.proofpilot.com. 

Stay informed about ProofPilot news at https://www.linkedin.com/company/proofpilot 

About Lokavant

Lokavant is the trailblazer in AI for Study Forecasting, transforming how clinical trials are planned and executed by delivering clarity in an uncertain industry. Its flagship solution, Spectrum, enables clinical teams to independently forecast enrollment timelines and assess operational risks – both before and during study execution. Powered by advanced AI models, including generative AI, machine learning, and causal AI, Lokavant delivers real-time forecasts with over 80% confidence in minutes. Sponsors and CROs use Spectrum to reduce non-conformance events by 70%, improve forecasting accuracy by 70x, and cut study timelines and costs. Learn more at www.lokavant.com.

Media Contact: Colleen yang, colleen@proofpilot.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/proofpilot-acquires-lokavant-to-transform-clinical-trial-performance-with-predictive-analytics-302555757.html

SOURCE ProofPilot